FY2025 EPS Estimates for MDxHealth Reduced by William Blair

MDxHealth SA (NASDAQ:MDXH) – Analysts at William Blair reduced their FY2025 earnings estimates for shares of MDxHealth in a research report issued to clients and investors on Thursday, November 13th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($0.61) per share for the year, down from their previous estimate of ($0.50). The consensus estimate for MDxHealth’s current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth’s Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.45) EPS.

A number of other research firms have also recently commented on MDXH. Weiss Ratings restated a “sell (e+)” rating on shares of MDxHealth in a research note on Wednesday, October 8th. Lake Street Capital increased their target price on MDxHealth from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. BTIG Research raised their target price on MDxHealth from $6.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, November 13th. TD Cowen boosted their price target on shares of MDxHealth from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Wall Street Zen raised shares of MDxHealth to a “hold” rating in a research report on Saturday, August 30th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, MDxHealth currently has an average rating of “Moderate Buy” and a consensus price target of $7.75.

MDxHealth Stock Performance

NASDAQ:MDXH opened at $3.21 on Monday. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $5.33. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.22 and a current ratio of 1.31. The company has a 50 day moving average price of $4.31 and a 200 day moving average price of $3.08. The stock has a market capitalization of $151.79 million, a P/E ratio of -3.65 and a beta of 1.68.

MDxHealth (NASDAQ:MDXH) last announced its earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The company had revenue of $27.43 million for the quarter, compared to analysts’ expectations of $24.11 million. MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%. MDxHealth has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On MDxHealth

A number of hedge funds have recently bought and sold shares of the stock. Lido Advisors LLC acquired a new position in shares of MDxHealth during the third quarter worth about $48,000. GSA Capital Partners LLP purchased a new position in MDxHealth in the third quarter worth approximately $48,000. Jefferies Financial Group Inc. acquired a new position in MDxHealth during the 3rd quarter worth approximately $53,000. Bank of America Corp DE grew its holdings in MDxHealth by 5,164.0% during the 3rd quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after acquiring an additional 14,769 shares in the last quarter. Finally, Millennium Management LLC purchased a new stake in shares of MDxHealth in the 3rd quarter valued at approximately $127,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.